Associated Papers
Von Willebrand Disease: From In Vivo to In Vitro Disease Models.
de Boer S et al.
Hemasphere, 2019
A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.
Veyradier A et al.
Medicine, 2016
New development in von Willebrand disease.
Castaman G
Current Opinion in Hematology, 2013
Weibel-Palade bodies: a window to von Willebrand disease.
Valentijn KM et al.
Journal of Thrombosis and Haemostasis : Jth, 2013
Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.
Jacobi PM et al.
Blood, 2012
Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation.
Castaman G et al.
Journal of Thrombosis and Haemostasis : Jth, 2012
C1272F: a novel type 2A von Willebrand's disease mutation in A1 domain; its clinical significance.
Woods AI et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia, 2012
Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage.
Haberichter SL et al.
Journal of Thrombosis and Haemostasis : Jth, 2009
Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A et al.
Acta Haematologica, 2009
Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion.
Hommais A et al.
Journal of Thrombosis and Haemostasis : Jth, 2006
Select a paper to view details